Damora Therapeutics (DMRA) Payables (2019 - 2026)
Damora Therapeutics posted quarterly Payables of $819000.0 for Q1 2026, up 131.36% year-on-year from $354000.0 in Q1 2025, and up 84.46% on a QoQ basis from $444000.0 in Q4 2025.
Damora Therapeutics (DMRA) has 8 years of Payables data on file, last reported at $819000.0 in Q1 2026.
- For the quarter ending Q1 2026, Payables rose 131.36% year-over-year to $819000.0; the trailing twelve-month figure through Mar 2026 stood at $819000.0 (up 131.36% YoY), and the FY2025 full-year result was $444000.0, up 17.77% from the prior year.
- Payables for Q1 2026 stood at $819000.0, up from $444000.0 in the prior quarter.
- Across five years, Payables topped out at $5.6 million in Q2 2023 and bottomed at $354000.0 in Q1 2025.
- The 5-year median for Payables is $1.7 million (2024), against an average of $1.9 million.
- The widest annual swing landed in 2023, when Payables jumped 134.77%; it then slumped 88.76% in 2024.
- A 5-year view of Payables shows it stood at $3.4 million in 2022, then plunged by 49.19% to $1.7 million in 2023, then sank by 77.85% to $377000.0 in 2024, then increased by 17.77% to $444000.0 in 2025, then jumped by 84.46% to $819000.0 in 2026.
- The last three Payables figures came in at $819000.0 (Q1 2026), $444000.0 (Q4 2025), and $520000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | 819,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 819,000.00 |
| Dec 31, 2025 | 444,000.00 |
| Sep 30, 2025 | 520,000.00 |
| Jun 30, 2025 | 756,000.00 |
| Mar 31, 2025 | 354,000.00 |
| Dec 31, 2024 | 377,000.00 |
| Sep 30, 2024 | 503,000.00 |
| Jun 30, 2024 | 724,000.00 |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 4.48 Mn |
| Jun 30, 2023 | 5.56 Mn |
| Mar 31, 2023 | 3.55 Mn |
| Dec 31, 2022 | 3.35 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 2.82 Mn |
| Mar 31, 2022 | 3.22 Mn |
| Dec 31, 2021 | 1.53 Mn |
| Sep 30, 2021 | 1.98 Mn |
| Jun 30, 2021 | 1.59 Mn |
| Mar 31, 2021 | 1.78 Mn |
| Dec 31, 2020 | 2.85 Mn |
| Sep 30, 2020 | 4.46 Mn |
| Dec 31, 2019 | 3.33 Mn |